Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.
Paradigm Biopharmaceuticals Ltd, a late-stage drug development company, has announced its Annual General Meeting (AGM) scheduled for 19 November 2024, with a director nomination deadline set for 30 September 2024. Shareholders will receive details in a forthcoming Notice of Meeting. The company specializes in developing treatments for inflammatory diseases, including a phase 3 study in osteoarthritis.
For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.
